Global Alliance of Leading Drug Discovery and Development Centers
Research Areas
At a Glance
- Status: Active Consortium
- Year Launched: 2013
- Initiating Organization: The Centre for Drug Research and Development (CDRD)
- Initiator Type: Academia
- No disease focus
- Location: International
Abstract
Through this Alliance, member organizations will collaborate on mutually-beneficial projects, share best practices, expertise and resources, and develop common standards and performance measurements – ultimately working together to improve the conversion of global early-stage technology into much needed therapies. All member organizations are fully-integrated translational centres capable of professionally advancing drug discovery projects along the value chain from idea to drug candidate with proof-of-concept. Together, they represent close to 400 experienced drug developers collaborating with tens of thousands of academic scientists around the globe on over 165 highly innovative therapeutic projects targeting significant unmet medical needs
Mission
The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network to ultimately improve the rate at which academic research is translated into new medicines.
Consortium History
Started in 2013
Structure & Governance
The six experienced drug discovery teams coordinate and leverage one another’s strengths.
Points of Contact
Karimah Es Sabar, President and CEO of CDRD
Sponsors & Partners
The Centre for Drug Research and Development (CDRD), Canada |
Lead Discovery Center (LDC), Germany |
The Scripps Research Institute, Scripps Florida, United States |
The Centre for Drug Design and Discovery (CD3), Belgium |
Medical Research Council Technology, United Kingdom |
Cancer Research Technology, United Kingdom |